ES2179187T3 - Oriteuba qye se yba a cd40 para estimular una respuesta inmune. - Google Patents

Oriteuba qye se yba a cd40 para estimular una respuesta inmune.

Info

Publication number
ES2179187T3
ES2179187T3 ES96909555T ES96909555T ES2179187T3 ES 2179187 T3 ES2179187 T3 ES 2179187T3 ES 96909555 T ES96909555 T ES 96909555T ES 96909555 T ES96909555 T ES 96909555T ES 2179187 T3 ES2179187 T3 ES 2179187T3
Authority
ES
Spain
Prior art keywords
immune response
oriteuba
qye
stimulate
going
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909555T
Other languages
English (en)
Inventor
Mark Alderson
Kim A Campbell
Mary K Kennedy
Charles R Maliszewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ES2179187T3 publication Critical patent/ES2179187T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCUBRE UN METODO PARA ESTIMULAR UNA RESPUESTA INMUNITARIA QUE COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UNA PROTEINA DE UNION A CD40. EL METODO ES UTIL EN EL TRATAMIENTO DE INDIVIDUOS INFECTADOS CON ORGANISMOS PATOGENOS U OPORTUNISTAS, E INDIVIDUOS CON UNA RESPUESTA INMUNITARIA CELULAR DISMINUIDA. LAS PROTEINAS DE UNION A CD40 INCLUYEN LIGANDO CD40, ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECIFICAMENTE A CD40 Y COMBINACIONES DE LOS MISMOS.
ES96909555T 1995-03-01 1996-02-29 Oriteuba qye se yba a cd40 para estimular una respuesta inmune. Expired - Lifetime ES2179187T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01

Publications (1)

Publication Number Publication Date
ES2179187T3 true ES2179187T3 (es) 2003-01-16

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909555T Expired - Lifetime ES2179187T3 (es) 1995-03-01 1996-02-29 Oriteuba qye se yba a cd40 para estimular una respuesta inmune.

Country Status (15)

Country Link
EP (1) EP0812206B1 (es)
JP (1) JP3657271B2 (es)
KR (1) KR19980702490A (es)
AT (1) ATE220331T1 (es)
AU (1) AU699291B2 (es)
CA (1) CA2213798C (es)
DE (1) DE69622259T2 (es)
DK (1) DK0812206T3 (es)
ES (1) ES2179187T3 (es)
FI (1) FI973484L (es)
MX (1) MX9706588A (es)
NO (1) NO973875L (es)
NZ (1) NZ305083A (es)
PT (1) PT812206E (es)
WO (1) WO1996026735A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
JP2001526241A (ja) * 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
ES2330017T3 (es) * 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
NO2525817T3 (es) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
MX2021012471A (es) 2019-04-11 2022-01-04 Univ Arkansas Aptameros de adn especificos de cd40 como adyuvantes de vacunas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283541B1 (ko) * 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
KR960704576A (ko) * 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 CD40에 대한 항체(Antibodies to CD40)

Also Published As

Publication number Publication date
NO973875L (no) 1997-10-31
NZ305083A (en) 1999-06-29
JP3657271B2 (ja) 2005-06-08
CA2213798C (en) 2001-02-06
DK0812206T3 (da) 2002-09-09
DE69622259T2 (de) 2003-03-27
AU5301196A (en) 1996-09-18
KR19980702490A (ko) 1998-07-15
DE69622259D1 (de) 2002-08-14
EP0812206B1 (en) 2002-07-10
CA2213798A1 (en) 1996-09-06
ATE220331T1 (de) 2002-07-15
MX9706588A (es) 1997-11-29
FI973484A7 (fi) 1997-10-24
FI973484L (fi) 1997-10-24
PT812206E (pt) 2002-11-29
NO973875D0 (no) 1997-08-22
WO1996026735A1 (en) 1996-09-06
JPH11506418A (ja) 1999-06-08
AU699291B2 (en) 1998-11-26
FI973484A0 (fi) 1997-08-25
EP0812206A1 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
AR007249A1 (es) Preparacion concentrada de anticuerpos
MX9304363A (es) Metodo para enlace intracelular de moleculas blanco.
EE9600192A (et) Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
NO963168D0 (no) Immunstimulatoriske monoklonale antistoffer
DE69228701D1 (de) Fragmente von Prion Proteinen.
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
FI902143A7 (fi) HIV-peptidit, keinotekoiset HIV-antigeenit ja immunomäärityspakkaukset
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
ATE267213T1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
EA200400134A1 (ru) Терапевтический агент
ES2072490T3 (es) Procedimiento para la pasteurizacion de la proteina tisular pp4.
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE69727491D1 (de) Verfahren zur verabreichung von wachstumsfaktoren
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
ES2107545T3 (es) Anticuerpos policlonales dirigidos contra la hirudina y su utilizacion para la identificacion, la purificacion inmunologica y la determinacion cuantitativa de la hirudina.
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
EA199900934A1 (ru) Применение микрочастиц, содержащих адсорбированные на них белок и антитела, для получения фармацевтической композиции для интраназального введения
DK0999849T3 (da) Anvendelse af LBP til sepsisbehandling